Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Re:NewCell in connection with a directed share issue (2)
Mandate

Vinge has advised Re:NewCell in connection with a directed share issue

June 30, 2023 Capital Markets and Public M&A

Vinge has advised Re:NewCell, a textile-to-textile recycling company listed on Nasdaq First North Premier Growth Market, in connection with a directed share issue whereby the company raised proceeds of approximately SEK 240 million before issue costs.

The share issue was directed to a number of selected Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Founded by innovators from Stockholm’s KTH Royal Institute of Technology in 2012, Re:NewCell AB (publ) is a multi-award-winning sustaintech company based in Sweden. The company’s vision is to make fashion circular.

Vinge’s team consisted of Dain Hård Nevonen, William Kåge and Annie Fällström.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026